Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and certain myelodysplastic syndromes in adult patients. The medication exerts anti‑proliferative, pro‑apoptotic, anti‑angiogenic and immunomodulatory actions by targeting cereblon, a component of the E3 ubiquitin ligase complex.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma cell proliferation or dysplastic marrow cells.

- Multiple myeloma: improves progression‑free survival and overall response rates. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Relapsed or refractory multiple myeloma: provides a therapeutic option after prior lines of therapy.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count. - Thrombocytopenia: lowered platelet count. - Fatigue: persistent tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Venous thromboembolism: formation of blood clots in veins. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers during therapy.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood counts: perform regular complete blood count assessments. - Assess thrombotic risk: evaluate patient history for clotting disorders. - Evaluate organ function: check renal and hepatic parameters periodically. - Avoid use in pregnancy: contraindicated due to teratogenic potential. - Counsel on contraception: ensure effective birth control during treatment and for a defined period after cessation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunomodulation.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate thrombocytopenia. - Digoxin: potential for altered serum concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide levels.